Overview
NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not provide an evidence submission.
Last reviewed: 12 August 2020
Next review: We will review this decision if the company decides to make a submission.